Market Overview

Research and Markets: Pre-Diabetes/Impaired Glucose Tolerance - Pipeline Review H2 2012


Research and Markets ( has announced the addition of Global Markets Direct's new report "Pre-Diabetes/Impaired Glucose Tolerance - Pipeline Review, H2 2012" to their offering.

This report provides information on the therapeutic development for Pre-Diabetes/Impaired Glucose Tolerance, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pre-Diabetes/Impaired Glucose Tolerance.

Pre-Diabetes/Impaired Glucose Tolerance - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


  • A snapshot of the global therapeutic scenario for Pre-Diabetes/Impaired Glucose Tolerance.
  • A review of the Pre-Diabetes/Impaired Glucose Tolerance products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Pre-Diabetes/Impaired Glucose Tolerance pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Pre-Diabetes/Impaired Glucose Tolerance.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Pre-Diabetes/Impaired Glucose Tolerance pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

View Comments and Join the Discussion!

Partner Center